Aptamer Group
plc
("Aptamer", the "Company" or
the "Group")
Partnership with Microsaic
Systems plc for Optimer-enabled water monitoring
- New binders will be
developed to multiple waterborne pathogens
- Optimer will support
continuous water monitoring for rapid detection
Aptamer Group plc (AIM: APTA), the
developer of novel Optimer® binders to enable innovation
in the life sciences industry, announces a partnership with
Microsaic Systems plc (Microsaic) to develop a panel of Optimer
binders for integration into a water testing system.
Microsaic has recently purchased the
Microtox® water testing system. Earlier work with
Aptamer's COVID-19 Optimer binders and this water testing system
showed successful integration and function of the Optimer in the
pathogen detector and superior detection performance compared to
alternative affinity ligands, such as Affimers. Successful trials
have previously taken place using the Optimer-enabled pathogen
detectors for COVID-19 within the UK wastewater system. Following
the Microtox® acquisition, Microsaic intends to further
develop the device to commerciality using a panel of Optimer
binders that specifically detect several major waterborne
pathogens.
Aptamer has reached Heads of Terms
with Microsaic for the development of a panel of Optimer binders to
advance the water testing system. Aptamer Group will develop a
number of new Optimer binders to common waterborne pathogens, such
as E.coli, Cholera,
Cryptosporidium, Legionella and Norovirus. Following development, the
binders will be available for integration into the water pathogen
detectors for the rapid and sensitive detection of multiple
pathogens of serious concern to public health. This continuous
water testing solution will allow the detection of pathogens in
real-time, without delays associated with sending samples for
laboratory-based testing, and has shown to be simply integrated
with nationwide water systems for early detection of potential
infections.
Dr
Arron Tolley, Chief Technical Officer of Aptamer Group,
said: "We are pleased to work with
Microsaic and support their development of the water testing
system. Applying the pathogen detector within national water
systems could help prevent disease outbreaks by rapidly identifying
specific hotspots. The robust nature of Optimer binders means that
they can work within tests as diverse as lab-based diagnostics and
environmental water monitoring. Previous work has demonstrated that
Optimer binders allow highly sensitive pathogen detection in the
wastewater testing system, and we are pleased to build on this with
the new team at Microsaic as they advance the platform to
commerciality. "
- ENDS
-
For further information, please
contact:
Aptamer Group plc
Steve Hull
|
+44 (0) 1904 217
404
|
SPARK Advisory Partners Limited - Nominated
Adviser
Andrew Emmott / Adam
Dawes
|
+44 (0) 20 3368
3550
|
Turner Pope Investments (TPI) Limited -
Broker
James Pope / Andrew
Thacker
|
+44 (0) 20 3657
0050
|
About Aptamer Group plc
Aptamer Group develops custom affinity binders
through its proprietary Optimer® platform to enable new
approaches in therapeutics, diagnostics, and research applications.
The Company strives to deliver transformational solutions that meet
the needs of life science researchers and
developers.
Optimer binders are oligonucleotide
affinity ligands that can function as an antibody alternative. The
global affinity ligand market is currently worth over $170
billion.
Aptamer has successfully delivered
projects for a range of global pharma companies, diagnostic
development companies, and research institutes, covering multiple
application areas with the objective of establishing
royalty-bearing licenses.